Deutsche Bank AG Acquires New Holdings in Disc Medicine, Inc. $IRON

Key Points

• Deutsche Bank initiated a position in Disc Medicine, purchasing 30,643 shares worth approximately $2.24 million. Institutional investors collectively own 83.70% of the company.
• Analyst sentiment remains generally positive, with 10 Buy ratings, one Hold and one Sell; the consensus rating is Moderate Buy with a $106.50 price target.
• Disc Medicine shares opened at $82.55, while the company reported quarterly EPS of -$1.54, beating expectations of -$1.71. Insiders have sold 153,612 shares worth $11.43 million over the past 90 days.

Deutsche Bank AG bought a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,643 shares of the company's stock, valued at approximately $2,241,000. Deutsche Bank AG owned 0.08% of Disc Medicine at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in shares of Disc Medicine during the 2nd quarter valued at $14,974,000. State of Wyoming bought a new stake in shares of Disc Medicine during the 2nd quarter valued at about $25,000. GSA Capital Partners LLP purchased a new position in shares of Disc Medicine during the second quarter worth about $1,194,000. Handelsbanken Fonder AB purchased a new position in shares of Disc Medicine during the second quarter worth about $929,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of Disc Medicine in the first quarter worth approximately $207,000. 83.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Disc Medicine in a research report on Friday, July 17th. Morgan Stanley reissued an "overweight" rating and issued a $90.00 price target on shares of Disc Medicine in a report on Monday, August 17th. Wedbush reaffirmed an "outperform" rating and set a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. HC Wainwright upped their target price on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Finally, Wall Street Zen raised Disc Medicine from a "sell" rating to a "hold" rating in a research note on Saturday, August 1st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Disc Medicine has a consensus rating of "Moderate Buy" and a consensus target price of $106.50.

Disc Medicine Stock Down 0.1%

Shares of NASDAQ:IRON opened at $82.55 on Friday. The stock has a market capitalization of $316.58 million, a P/E ratio of -12.55 and a beta of 1.00. The stock's 50-day moving average price is $76.79 and its 200-day moving average price is $69.97. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, equities analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Insider Buying and Selling at Disc Medicine

In related news, COO Jonathan Yen-Wen Yu sold 8,796 shares of Disc Medicine stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total value of $731,123.52. Following the transaction, the chief operating officer directly owned 54,324 shares of the company's stock, valued at $4,515,410.88. The trade was a 13.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John D. Quisel sold 33,000 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the sale, the chief executive officer owned 226,064 shares of the company's stock, valued at $17,892,965.60. This represents a 12.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 153,612 shares of company stock worth $11,431,811. 3.76% of the stock is currently owned by insiders.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source